DuPont/Barr Enter Into Legal Truce With Five Product Promotion Accord
Executive Summary
DuPont expects to begin marketing a Barr-developed oncology product in the first quarter of 2001 under an agreement reached by the two companies in their Coumadin dispute.
You may also be interested in...
Pfizer’s Omnitrope Options Include Approval Challenge, Substitutability Fight
Pfizer's response to the approval of Sandoz' Omnitrope could signal the extent to which industry gauges the legality of approving follow-on biologics under the 505(b)(2) pathway
Pfizer’s Omnitrope Options Include Approval Challenge, Substitutability Fight
Pfizer's response to the approval of Sandoz' Omnitrope could signal the extent to which industry gauges the legality of approving follow-on biologics under the 505(b)(2) pathway
Bristol Buys DuPont: Re-Enters Imaging Agents, Adds To HIV Line
Bristol-Myers Squibb will re-enter the radiopharmaceutical business via the acquisition of DuPont Pharma.